NRx Pharmaceuticals, Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update Life Science Investing
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association 2026 Congress Life Science Investing
Topline Results from Phase 2 CELIA Study of Diranersen : First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease Life Science Investing
Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements Life Science Investing
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update Life Science Investing
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results Life Science Investing
Seer Reports First Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook Life Science Investing
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates Life Science Investing
